$TNXP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Tonix Pharmaceuticals Holding Corp..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Tonix Pharmaceuticals Holding Corp.. Get notifications about new insider transactions in Tonix Pharmaceuticals Holding Corp. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 18 2017 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 3.00 | 15,000 | 45,068 | 50,000 | 35 K to 50 K (+42.86 %) |
Aug 18 2017 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 2.99 | 5,000 | 14,950 | 35,000 | 30 K to 35 K (+16.67 %) |
Jun 30 2017 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Sell | S | 4.28 | 6,105 | 26,117 | 5,895 | 12 K to 5.9 K (-50.87 %) |
Jun 30 2017 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 4.33 | 5,000 | 21,640 | 30,000 | 25 K to 30 K (+20.00 %) |
Jun 26 2017 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 4.40 | 5,000 | 22,000 | 25,000 | 20 K to 25 K (+25.00 %) |
Jun 21 2017 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | A | 4.18 | 20,000 | 83,600 | 20,000 | |
Jun 21 2017 | TNXP | Tonix Pharmaceutic ... | DAVIDSON STUART | Director | Option Exercise | A | 4.18 | 20,000 | 83,600 | 20,000 | |
Jun 21 2017 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 4.18 | 20,000 | 83,600 | 20,000 | |
Jun 21 2017 | TNXP | Tonix Pharmaceutic ... | MATHER CHARLES E IV | Director | Option Exercise | A | 4.18 | 20,000 | 83,600 | 20,000 | |
Jun 21 2017 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Option Exercise | A | 4.18 | 30,000 | 125,400 | 30,000 | |
Jun 21 2017 | TNXP | Tonix Pharmaceutic ... | LANDRY DONALD W | Director | Option Exercise | A | 4.18 | 20,000 | 83,600 | 20,000 | |
Jun 21 2017 | TNXP | Tonix Pharmaceutic ... | GRACE PATRICK P | Director | Option Exercise | A | 4.18 | 20,000 | 83,600 | 20,000 | |
Jun 20 2017 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 4.22 | 20,000 | 84,400 | 20,000 | 0 to 20 K |
Mar 01 2017 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | A | 0.55 | 160,000 | 88,000 | 160,000 | |
Mar 01 2017 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | A | 0.55 | 160,000 | 88,000 | 160,000 | |
Mar 01 2017 | TNXP | Tonix Pharmaceutic ... | SAENGER BRADLEY | Chief Financial Off ... | Option Exercise | A | 0.55 | 47,500 | 26,125 | 47,500 | |
Mar 01 2017 | TNXP | Tonix Pharmaceutic ... | SAENGER BRADLEY | Chief Financial Off ... | Option Exercise | A | 0.55 | 47,500 | 26,125 | 47,500 | |
Mar 01 2017 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Option Exercise | A | 0.55 | 75,000 | 41,250 | 75,000 | |
Mar 01 2017 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Option Exercise | A | 0.55 | 75,000 | 41,250 | 75,000 | |
Nov 28 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 0.41 | 120,000 | 48,600 | 120,000 | 0 to 120 K |
Nov 22 2016 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 0.43 | 98,000 | 41,924 | 133,000 | 35 K to 133 K (+280.00 %) |
Oct 31 2016 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | P | 0.63 | 10,000 | 6,300 | 10,000 | |
Oct 31 2016 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 0.00 | 10,000 | 0 | 90,815 | 80.8 K to 90.8 K (+12.37 %) |
Oct 31 2016 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Option Exercise | P | 0.63 | 25,000 | 15,750 | 25,000 | |
Oct 31 2016 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Buy | P | 0.00 | 25,000 | 0 | 137,196 | 112.2 K to 137.2 K (+22.28 %) |
Oct 31 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | P | 0.63 | 100,000 | 63,000 | 100,000 | |
Oct 31 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 0.00 | 100,000 | 0 | 630,724 | 530.7 K to 630.7 K (+18.84 %) |
Sep 14 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 0.79 | 100,000 | 79,180 | 530,724 | 430.7 K to 530.7 K (+23.22 %) |
Jun 22 2016 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 2.08 | 20,000 | 41,500 | 20,000 | 0 to 20 K |
Jun 21 2016 | TNXP | Tonix Pharmaceutic ... | SAENGER BRADLEY | Chief Financial Off ... | Buy | P | 2.00 | 2,000 | 4,000 | 6,039 | 4 K to 6 K (+49.52 %) |
Jun 21 2016 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Buy | P | 2.00 | 25,000 | 50,000 | 63,550 | 38.6 K to 63.6 K (+64.85 %) |
Jun 21 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 2.00 | 50,000 | 100,000 | 430,724 | 380.7 K to 430.7 K (+13.13 %) |
Jun 21 2016 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 2.00 | 25,000 | 50,000 | 31,000 | 6 K to 31 K (+416.67 %) |
Jun 21 2016 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Buy | P | 2.00 | 25,000 | 50,000 | 112,196 | 87.2 K to 112.2 K (+28.67 %) |
Jun 21 2016 | TNXP | Tonix Pharmaceutic ... | DAUGHERTY BRUCE | See remarks | Buy | P | 2.00 | 100,000 | 200,000 | 100,000 | 0 to 100 K |
Jun 03 2016 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Buy | P | 2.50 | 20,000 | 49,916 | 43,185 | 23.2 K to 43.2 K (+86.26 %) |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Option Exercise | A | 0.00 | 11,250 | 0 | 11,250 | |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | DAVIDSON STUART | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | MATHER CHARLES E IV | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | SAENGER BRADLEY | Chief Financial Off ... | Option Exercise | A | 2.42 | 60,000 | 145,200 | 60,000 | |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | SAENGER BRADLEY | Chief Financial Off ... | Option Exercise | A | 2.42 | 20,000 | 48,400 | 20,000 | |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | GRACE PATRICK P | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | LANDRY DONALD W | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
May 31 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
May 12 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 2.30 | 31,042 | 71,356 | 380,724 | 349.7 K to 380.7 K (+8.88 %) |
May 11 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 2.24 | 8,210 | 18,399 | 349,682 | 341.5 K to 349.7 K (+2.40 %) |
Mar 23 2016 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 2.44 | 8,000 | 19,537 | 80,815 | 72.8 K to 80.8 K (+10.99 %) |
Mar 17 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 2.29 | 75,000 | 171,713 | 341,472 | 266.5 K to 341.5 K (+28.15 %) |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | DAVIDSON STUART | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Option Exercise | A | 0.00 | 11,250 | 0 | 0 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | GRACE PATRICK P | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | MATHER CHARLES E IV | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Option Exercise | A | 5.03 | 30,000 | 150,900 | 30,000 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Option Exercise | A | 5.03 | 30,000 | 150,900 | 30,000 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | MORRIS JESSICA EDGAR | Acting Chief Financ ... | Option Exercise | A | 5.03 | 30,000 | 150,900 | 30,000 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | MORRIS JESSICA EDGAR | Acting Chief Financ ... | Option Exercise | A | 5.03 | 30,000 | 150,900 | 30,000 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | LANDRY DONALD W | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | A | 5.03 | 110,000 | 553,300 | 110,000 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | A | 5.03 | 110,000 | 553,300 | 110,000 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | DAUGHERTY BRUCE | See Remarks | Option Exercise | A | 5.03 | 30,000 | 150,900 | 30,000 | |
Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | DAUGHERTY BRUCE | See Remarks | Option Exercise | A | 5.03 | 30,000 | 150,900 | 30,000 | |
Sep 30 2015 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Buy | P | 5.18 | 5,000 | 25,900 | 16,925 | 11.9 K to 16.9 K (+41.93 %) |
Sep 29 2015 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Buy | P | 5.83 | 400 | 2,330 | 19,260 | 18.9 K to 19.3 K (+2.12 %) |
Sep 28 2015 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Buy | P | 5.95 | 4,694 | 27,925 | 11,925 | 7.2 K to 11.9 K (+64.91 %) |
Sep 25 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 6.50 | 6,000 | 39,000 | 71,074 | 65.1 K to 71.1 K (+9.22 %) |
Aug 27 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 6.05 | 10,000 | 60,500 | 260,472 | 250.5 K to 260.5 K (+3.99 %) |
Aug 26 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 6.40 | 1,468 | 9,395 | 250,472 | 249 K to 250.5 K (+0.59 %) |
Aug 25 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 6.20 | 2,532 | 15,698 | 249,004 | 246.5 K to 249 K (+1.03 %) |
Aug 20 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 6.64 | 6,000 | 39,867 | 246,472 | 240.5 K to 246.5 K (+2.50 %) |
Aug 17 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 6.93 | 15,000 | 104,018 | 240,472 | 225.5 K to 240.5 K (+6.65 %) |
Jul 17 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 7.50 | 6,000 | 45,000 | 6,000 | 0 to 6 K |
Jul 17 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 7.50 | 25,000 | 187,500 | 225,472 | 200.5 K to 225.5 K (+12.47 %) |
Jul 17 2015 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Buy | P | 7.50 | 1,000 | 7,500 | 18,860 | 17.9 K to 18.9 K (+5.60 %) |
Jul 17 2015 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Buy | P | 7.50 | 10,000 | 75,000 | 32,550 | 22.6 K to 32.6 K (+44.35 %) |
Jul 17 2015 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Buy | P | 7.50 | 6,000 | 45,000 | 81,196 | 75.2 K to 81.2 K (+7.98 %) |
Jun 11 2015 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Buy | P | 8.38 | 4,500 | 37,710 | 7,231 | 2.7 K to 7.2 K (+164.77 %) |
Mar 17 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 7.18 | 1,000 | 7,180 | 65,074 | 64.1 K to 65.1 K (+1.56 %) |
Mar 17 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 6.85 | 1,000 | 6,853 | 64,074 | 63.1 K to 64.1 K (+1.59 %) |
Mar 13 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 7.21 | 1,000 | 7,210 | 63,074 | 62.1 K to 63.1 K (+1.61 %) |
Mar 13 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 7.26 | 1,000 | 7,260 | 62,074 | 61.1 K to 62.1 K (+1.64 %) |
Mar 11 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 7.00 | 1,000 | 7,000 | 61,074 | 60.1 K to 61.1 K (+1.66 %) |
Mar 11 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 6.90 | 1,000 | 6,900 | 60,074 | 59.1 K to 60.1 K (+1.69 %) |
Mar 10 2015 | TNXP | Tonix Pharmaceutic ... | MATHER CHARLES E IV | Director | Buy | P | 6.80 | 1,000 | 6,800 | 11,830 | 10.8 K to 11.8 K (+9.23 %) |
Mar 09 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 6.50 | 1,000 | 6,500 | 59,074 | 58.1 K to 59.1 K (+1.72 %) |
Mar 09 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 6.45 | 1,000 | 6,450 | 58,074 | 57.1 K to 58.1 K (+1.75 %) |
Mar 06 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 6.57 | 4,000 | 26,280 | 200,472 | 196.5 K to 200.5 K (+2.04 %) |
Mar 05 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 6.48 | 1,000 | 6,480 | 57,074 | 56.1 K to 57.1 K (+1.78 %) |
Mar 05 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 6.05 | 1,000 | 6,050 | 56,074 | 55.1 K to 56.1 K (+1.82 %) |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Option Exercise | A | 5.95 | 7,500 | 44,625 | 7,500 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | A | 5.95 | 5,000 | 29,750 | 5,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 5.95 | 5,000 | 29,750 | 5,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | GRACE PATRICK P | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | GRACE PATRICK P | Director | Option Exercise | A | 5.95 | 5,000 | 29,750 | 5,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Option Exercise | A | 5.95 | 26,500 | 157,675 | 26,500 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | DAUGHERTY BRUCE | See Remarks | Option Exercise | A | 5.95 | 36,000 | 214,200 | 36,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Option Exercise | A | 5.95 | 50,000 | 297,500 | 50,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | MATHER CHARLES E IV | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | MATHER CHARLES E IV | Director | Option Exercise | A | 5.95 | 5,000 | 29,750 | 5,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | DAVIDSON STUART | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | DAVIDSON STUART | Director | Option Exercise | A | 5.95 | 5,000 | 29,750 | 5,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | LANDRY DONALD W | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | LANDRY DONALD W | Director | Option Exercise | A | 5.95 | 5,000 | 29,750 | 5,000 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | A | 5.95 | 7,143 | 42,501 | 7,143 | |
Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | A | 5.95 | 189,000 | 1,124,550 | 189,000 | |
Feb 09 2015 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | P | 5.85 | 30,000 | 175,500 | 196,472 | 166.5 K to 196.5 K (+18.02 %) |
Feb 09 2015 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | P | 5.85 | 5,000 | 29,250 | 55,074 | 50.1 K to 55.1 K (+9.99 %) |
Feb 09 2015 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Buy | P | 5.85 | 5,000 | 29,250 | 17,860 | 12.9 K to 17.9 K (+38.88 %) |
Dec 19 2014 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | X | 4.25 | 30,000 | 127,500 | 0 | |
Dec 19 2014 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | X | 4.25 | 30,000 | 127,500 | 166,472 | 136.5 K to 166.5 K (+21.98 %) |
Dec 17 2014 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Option Exercise | X | 4.25 | 3,530 | 15,003 | 0 | |
Dec 17 2014 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Buy | X | 4.25 | 3,530 | 15,003 | 12,860 | 9.3 K to 12.9 K (+37.83 %) |
Nov 03 2014 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Option Exercise | A | 6.68 | 7,500 | 50,100 | 7,500 | |
Nov 03 2014 | TNXP | Tonix Pharmaceutic ... | MATHER CHARLES E IV | Director | Option Exercise | A | 6.68 | 5,000 | 33,400 | 5,000 | |
Nov 03 2014 | TNXP | Tonix Pharmaceutic ... | KELLERMAN DONALD J | See Remarks | Option Exercise | A | 6.68 | 36,000 | 240,480 | 36,000 | |
Nov 03 2014 | TNXP | Tonix Pharmaceutic ... | GRACE PATRICK P | Director | Option Exercise | A | 6.68 | 5,000 | 33,400 | 5,000 | |
Nov 03 2014 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Option Exercise | A | 6.68 | 26,500 | 177,020 | 26,500 | |
Nov 03 2014 | TNXP | Tonix Pharmaceutic ... | DAUGHERTY BRUCE | See Remarks | Option Exercise | A | 6.68 | 36,000 | 240,480 | 36,000 | |
Nov 03 2014 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Option Exercise | A | 6.68 | 38,000 | 253,840 | 38,000 | |
Nov 03 2014 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | A | 6.68 | 100,000 | 668,000 | 100,000 | |
Oct 31 2014 | TNXP | Tonix Pharmaceutic ... | LANDRY DONALD W | Director | Option Exercise | A | 6.68 | 5,000 | 33,400 | 5,000 | |
Oct 31 2014 | TNXP | Tonix Pharmaceutic ... | DAVIDSON STUART | Director | Option Exercise | A | 6.68 | 5,000 | 33,400 | 5,000 | |
Oct 31 2014 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 6.68 | 5,000 | 33,400 | 5,000 | |
Oct 31 2014 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | A | 6.68 | 5,000 | 33,400 | 5,000 | |
Sep 29 2014 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | X | 4.25 | 10,000 | 42,500 | 30,000 | |
Sep 29 2014 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | X | 4.25 | 10,000 | 42,500 | 136,472 | 126.5 K to 136.5 K (+7.91 %) |
Aug 27 2014 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | X | 4.25 | 7,059 | 30,001 | 40,000 | |
Aug 27 2014 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Buy | X | 4.25 | 7,059 | 30,001 | 126,472 | 119.4 K to 126.5 K (+5.91 %) |
Jun 23 2014 | TNXP | Tonix Pharmaceutic ... | LANDRY DONALD W | Director | Option Exercise | A | 9.87 | 5,000 | 49,350 | 5,000 | |
Jun 20 2014 | TNXP | Tonix Pharmaceutic ... | GRACE PATRICK P | Director | Option Exercise | A | 9.87 | 5,000 | 49,350 | 5,000 | |
Jun 23 2014 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 9.87 | 5,000 | 49,350 | 5,000 | |
Jun 20 2014 | TNXP | Tonix Pharmaceutic ... | KELLERMAN DONALD J | See Remarks | Option Exercise | A | 9.87 | 36,000 | 355,320 | 36,000 | |
Jun 20 2014 | TNXP | Tonix Pharmaceutic ... | MATHER CHARLES E IV | Director | Option Exercise | A | 9.87 | 5,000 | 49,350 | 0 | |
Jun 20 2014 | TNXP | Tonix Pharmaceutic ... | SULLIVAN GREGORY M | Chief Medical Offic ... | Option Exercise | A | 9.87 | 26,500 | 261,555 | 0 | |
Jun 20 2014 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Option Exercise | A | 9.87 | 100,000 | 987,000 | 100,000 | |
Jun 19 2014 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Option Exercise | A | 9.87 | 30,000 | 296,100 | 30,000 | |
Jun 19 2014 | TNXP | Tonix Pharmaceutic ... | DAUGHERTY BRUCE | See Remarks | Option Exercise | A | 9.87 | 25,000 | 246,750 | 25,000 | |
Jun 19 2014 | TNXP | Tonix Pharmaceutic ... | MARIO ERNEST | Director | Option Exercise | A | 9.87 | 5,000 | 49,350 | 5,000 | |
Jun 19 2014 | TNXP | Tonix Pharmaceutic ... | DAVIDSON STUART | Director | Option Exercise | A | 9.87 | 5,000 | 49,350 | 5,000 | |
Jun 19 2014 | TNXP | Tonix Pharmaceutic ... | Rhodes John B | Director | Option Exercise | A | 9.87 | 7,500 | 74,025 | 7,500 | |
Jun 17 2014 | TNXP | Tonix Pharmaceutic ... | GRACE PATRICK P | Director | Option Exercise | A | 15.88 | 5,500 | 87,340 | 5,500 | |
Mar 21 2014 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | J | 12.15 | 25,000 | 303,750 | 29,167 | 4.2 K to 29.2 K (+599.95 %) |
Mar 21 2014 | TNXP | Tonix Pharmaceutic ... | LEDERMAN SETH | Chief Executive Off ... | Buy | J | 12.15 | 25,000 | 303,750 | 29,167 | 4.2 K to 29.2 K (+599.95 %) |
Mar 04 2014 | TNXP | Tonix Pharmaceutic ... | GERSHELL LELAND | Chief Financial Off ... | Option Exercise | A | 15.88 | 32,000 | 508,160 | 32,000 | |
Feb 28 2014 | TNXP | Tonix Pharmaceutic ... | DAVIDSON STUART | Director | Option Exercise | A | 15.88 | 5,500 | 87,340 | 5,500 |